AN2 Therapeutics Operating Income

AN2 Therapeutics (ANTX) currently reports a operating income of $-37M as of March 2026. That compares with $-50M in the prior-year period — up 25.8% year over year. Use the charts on this page to explore AN2 Therapeutics's operating income history and peer comparisons.

AN2 Therapeutics's operating income increased from $-50M to $-37M — a 25.8% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

AN2 Therapeutics reported $-37M in operating income as of March 2026. That compares with $-50M in the prior-year period — up 25.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-37M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for AN2 Therapeutics, and consider following ANTX for alerts when major investors trade the stock.